This is a routine conference presentation announcement with no material new information. Monitor the June 4 presentation for any pipeline updates, but do not trade on this filing alone. The next catalyst is the Phase 2 topline readout expected mid-2026.
Price Chart
Executive Summary
Turn Therapeutics (TTRX) announced that CEO Bradley Burnam will present at the Jefferies Global Healthcare Conference 2026 on June 4. The press release restates the company's pipeline positioning for GX-03 (Phase 2 atopic dermatitis trial with topline results expected mid-2026) but contains no new financial data, clinical data, or material corporate developments.
Key Facts
- CEO to present at Jefferies Global Healthcare Conference on June 4, 2026 at 9:55-10:25 AM EDT
- Lead asset GX-03 is a first-in-class topical IL-36/IL-31 inhibitor in Phase 2 for moderate-to-severe atopic dermatitis
- Topline Phase 2 results expected mid-2026
- No new financial, clinical, or guidance data disclosed in the filing
Financial Impact
No financial data disclosed
Risk Factors
- Phase 2 trial failure risk for GX-03
- No revenue or near-term commercialization path as a clinical-stage biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-058730 |
| Document: ea029141001ex99-1.htm | 0001213900-26-058730 |
| Document: 0001213900-26-058730-index-headers.html | 0001213900-26-058730 |
| Document: 0001213900-26-058730-index.html | 0001213900-26-058730 |
| Document: 0001213900-26-058730.txt | 0001213900-26-058730 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $10.47 | awaiting T+60 | — | $10.54 (+0.67%) |
Oct 6, 2026 20d ago | 8-K | $12.10 | awaiting T+60 | — | $10.54 (−12.89%) |
Sep 10, 2026 6w ago | 8-K | $13.38 | awaiting T+60 | — | $10.54 (−21.23%) |
Sep 9, 2026 6w ago | 8-K | $13.75 | awaiting T+60 | — | $10.54 (−23.35%) |
Aug 18, 2026 10w ago | 8-K | $9.99 | awaiting T+60 | — | $10.54 (+5.51%) |
Jul 7, 2026 16w ago | 8-K | $9.71 $14.39 | ▲ +48.20% | ▲ +46.20% | $10.54 (+8.55%) |
Jun 3, 2026 20w ago | 8-K | $6.02 $10.11 | ▲ +67.94% | ▲ +65.44% | $10.54 (+75.08%) |
Jun 1, 2026 21w ago | 8-K | $6.33 $9.73 | ▲ +53.71% | ▲ +52.48% | $10.54 (+66.51%) |
May 27, 2026 21w ago | 8-K | $5.29 $9.54 | ▲ +80.34% | ▲ +78.46% | $10.54 (+99.24%) |
May 19, 2026 23w ago | 8-K | $4.55 $9.86 | ▲ +116.70% | ▲ +110.41% | $10.54 (+131.65%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers